Phosphorylated T567 ezrin is associated with merlin expression in KIT-mutant gastrointestinal stromal tumors

Molecular Medicine Reports

Volumn 5, Issue 1, 2012, Pages 17-21

  Weng, Wen Hui ^a   Yeh, Chun Nan ^b   Cheng, Yung Feng ^a   Lenka, Govinda ^a   Liaw, Yi Wei ^a  

^a NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Ezrin; KIT; Merlin; P ezrinThr567; P ezrinTyr146; P ezrinTyr353

Indexed keywords

EZRIN; MERLIN; STEM CELL FACTOR RECEPTOR; THREONINE;

ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE; CYTOSKELETAL PROTEINS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; NEUROFIBROMIN 2; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84855212128     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.609     Document Type: Article

References (46)

1. Khanna C, Wan X, Bose S, et al: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10: 182-186, 2004. (Pubitemid 38524889)
2. Yu Y, Khan J, Khanna C, et al: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10: 175-181, 2004. (Pubitemid 38524888)
3. Kim C, Shin E, Hong S, et al: Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 41: 138-144, 2009.
4. Xu-Dong S, Zan S, Shui-er Z, et al: Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med 32: E180-188, 2009.
5. Park HR, Cabrini RL, Araujo ES, et al: Expression of ezrin and metastatic tumor antigen in osteosarcomas of the jaw. Tumori 95: 81-86, 2009.
6. Elliott BE, Meens JA, SenGupta SK, et al: The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7: R365-R373, 2005.
7. Li Q, Wu M, Wang H, et al: Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 261: 55-63, 2008.
8. Nestl A, Von Stein OD, Zatloukal K, et al: Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61: 1569-1577, 2001. (Pubitemid 34292589)
9. Weng WH, Ahlen J, Astrom K, et al: Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11: 6198-6204, 2005. (Pubitemid 41262948)
10. Moilanen J, Lassus H, Leminen A, et al: Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 90: 273-281, 2003. (Pubitemid 36952014)
11. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45, 2003. (Pubitemid 36077255)
12. Takeuchi K, Kawashima A, Nagafuchi A, et al: Structural diversity of band 4.1 superfamily members. J Cell Sci 107: 1921-1928, 1994. (Pubitemid 24226442)
13. Monni R, Haddaoui L, Naba A, et al: Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia. Blood 111: 3163.3172, 2008.
14. Fievet BT, Gautreau A, Roy C, et al: Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol 164: 653-659, 2004. (Pubitemid 38282949)
15. Orian-Rousseau V, Chen L, Sleeman JP, et al: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 3074-3086, 2002. (Pubitemid 35424194)
16. Martin TA, Harrison G, Mansel RE, et al: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46: 165-186, 2003. (Pubitemid 36452345)
17. Kansas GS, Muirhead MJ and Dailey MO: Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 76: 2483-2492, 1990.
18. Legras S, Gunthert U, Stauder R, et al: A strong expression of CD44.6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 91: 3401-3413, 1998. (Pubitemid 28193893)
19. Pujuguet P, Del Maestro L, Gautreau A, et al: Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 14: 2181-2191, 2003. (Pubitemid 36583562)
20. Dard N, Louvet-Vallee S, Santa-Maria A, et al: Phosphorylation of ezrin on threonine T567 plays a crucial role during compaction in the mouse early embryo. Dev Biol 271: 87-97, 2004. (Pubitemid 38757777)
21. Sherman L, Jacoby LB, Lampe J, et al: CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene. Cancer Res 57: 4889-4897, 1997. (Pubitemid 27468999)
22. Gutmann DH, Geist RT, Xu H, et al: Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 7: 335-345,1998. (Pubitemid 28120620)
23. Okada T, You L and Giancotti FG: Shedding light on Merlin's wizardry. Trends Cell Biol 17: 222-229, 2007. (Pubitemid 46679247)
24. Agaram NP, Besmer P, Wong GC, et al: Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13: 170-181, 2007. (Pubitemid 46121866)
25. Stamatakos M, Douzinas E, Stefanaki C, et al: Gastrointestinal stromal tumor. World J Surg Oncol 7: 61, 2009.
26. Heinrich MC, Rubin BP, Longley BJ, et al: Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33: 484-495, 2002.
27. Corless CL, Fletcher JA and Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825, 2004. (Pubitemid 41095223)
28. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003. (Pubitemid 36159485)
29. Wei YC, Li CF, Yu SC, et al: Ezrin overexpression in gastro-intestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location. Mod Pathol 22: 1351-1360, 2009.
30. Pan CC, Chen PC and Chiang H: Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 121: 878-883, 2004. (Pubitemid 38669283)
31. Stec R, Grala B, Maczewski M, et al: Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res 28: 134, 2009.
32. Yamazaki K, Sakamoto M, Ohta T, et al: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 22: 847-852, 2003. (Pubitemid 36255820)
33. Lin ZH, Han EM, Lee ES, et al: A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol 17: 611-616, 2004. (Pubitemid 38715481)
34. Tuveson DA, Willis NA, Jacks T, et al: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058, 2001. (Pubitemid 32769795)
35. Bauer S, Yu LK, Demetri GD, et al: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153-9161, 2006. (Pubitemid 44521135)
36. Gould KL, Cooper JA, Bretscher A, et al: The protein-tyrosine kinase substrate, p81, is homologous to a chicken microvillar core protein. J Cell Biol 102: 660-669, 1986. (Pubitemid 16140828)
37. Lee JY, Moon HJ, Lee WK, et al: Merlin facilitates ubiquitination and degradation of transactivation-responsive RNA-binding protein. Oncogene 25: 1143-1152, 2006.
38. Yeh CN, Pang ST, Chen TW, et al: Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma. BMC Cancer 9: 233, 2009.
39. Valdman A, Fang X, Pang ST, et al: Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol 48: 852-857, 2005.
40. Jeon S, Kim NH, Kim JY, et al: Stem cell factor induces ERM protein phosphorylation through PI3K activation to mediate melanocyte proliferation and migration. Pigment Cell Melanoma Res 22: 77-85, 2009.
41. Di Cristofano C, Leopizzi M, Miraglia A, et al: Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol 23: 1012-1020, 2010.
42. Cui Y, Li T, Zhang, et al: Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest 28: 242-247, 2010.
43. Legg JW and Isacke CM: Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr Biol 8: 705-708, 1998. (Pubitemid 28286278)
44. Morrison H, Sperka T, Manent J, et al: Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67: 520-527, 2007. (Pubitemid 46192188)
45. Thurneysen C, Opitz I, Kurtz S, et al: Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64: 140-147, 2009.
46. Fraenzer JT, Pan H, Minimo L Jr, et al: Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23: 1493-1500, 2003.